Clinical trials: First Line Treatment
Ovarian Cancer, Fallopian Tube Cancer
Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Primary Objective: 1. Evaluate the efficacy of letrozole to increase the duration of progression-free survival (defined as time to earliest occurrence of local or distant recurrence or clinically significant elevation in CA-125)…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00634894
- Testing
- Femara
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Afrezza® INHALE-1 Study in Pediatrics
INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine…
- Trial name
- INHALE-1 (NCT04974528)
- Testing
- Afrezza, Rapid-acting Insulin Analog, Basal Insulin
- Where
- 39 sites in United States
- Volunteers
- 319 people
- Sponsor
- Mannkind Corporation
Visceral Leishmaniasis
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
The purpose of this study is to assess the efficacy and safety of SSG 30 days alone, PM 21 days alone and SSG and PM as a combination course of 17 days in the treatment of patients with VL.
- Trial name
- NCT00255567
- Testing
- Sodium Stibogluconate, Paromomycin sulphate, SSG and Paromomycin sulphate
- Where
- 5 sites in Ethiopia, Kenya and 2 more
- Volunteers
- 1,142 people
- Sponsor
- Drugs for Neglected Diseases
Small Cell Lung Carcinoma
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
Small cell lung cancer (SCLC), characterized by rapid proliferation, high growth fraction and early development of metastases, is the most aggressive form of lung cancer.
- Trial name
- ARSENAL (NCT05683977)
- Testing
- durvalumab
- Where
- 34 sites in France
- Volunteers
- 254 people
- Sponsor
- AstraZeneca
Leukemia
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276601
- Testing
- arsenic trioxide, cytarabine, daunorubicin hydrochloride
- Where
- 7 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Depression
The Omega-3 Fatty Acid Paediatric Depression Trial
This study investigates the therapeutic efficacy and safety of omega-3 fatty acids rich in eicosapentaenoic acid / docosahexaenoic acid in pediatric depression in a nine months double-blind multi-centre study in 220 children and…
- Trial name
- Omega-3-pMDD (NCT03167307)
- Testing
- Omega 3 fatty acid
- Where
- 7 sites in Switzerland
- Volunteers
- 257 people
- Sponsor
- Gregor Berger
HIV Infections, AIDS
Test Albuvirtide in Experienced Patients
The purpose of this study is to evaluate the efficacy and safety of albuvirtide combined with lopinavir-ritonavir (LPV/r) in HIV-1-infected patients who failed first-line antiretroviral therapy (ART).
- Trial name
- TALENT (NCT02369965)
- Testing
- albuvirtide, lopinavir-ritonavir, tenofovir
- Where
- 12 sites in China
- Volunteers
- 418 people
- Sponsor
- Frontier Biotechnologies Inc.
Crohn Disease
Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease
To explore the safety and effectiveness of repeated and multiple fecal microbiota transplantations (FMTs) plus partial enteral nutrition (PEN) as a first-line treatment for active Crohn's disease (CD) in children.
- Trial name
- FMT (NCT05321758)
- Testing
- Fecal Microbiota Transplantation, Immunosuppressive Agents
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Graft vs Host Disease
Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease
The purpose of this Phase I/II, open-label, dose-escalation study is to evaluate an investigational monoclonal antibody administered as a first-line therapy to patients with acute, Grade II, III, or IV graft-versus-host disease…
- Trial name
- NCT00032292
- Testing
- Visilizumab
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- Facet Biotech
Carcinoma, Non-Small-Cell Lung
A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
A Multicountry, Multicenter, Non-interventional, Retrospective Study to determine Real-world treatment patterns and associated outcomes after FIRST LINE Osimertinib in patients with advanced and Metastatic NSCLC harboring…
- Trial name
- TREASURE (NCT06039683)
- Where
- 7 sites in Kuwait, Qatar and 2 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Malaria Falciparum
Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
This implementation study evaluated the health systems feasibility, economic costs, and stakeholder acceptability of deploying multiple first-line therapies (MFTs) that were of the artemisinin-based combination therapies (ACTs)…
- Trial name
- NCT07362498
- Testing
- Artemether + Lumefantrine, Dihydroartemisin-piperaquine, Artesunate-Amodiaquine (AS-AQ)
- Where
- 2 sites in Kenya
- Volunteers
- 316 people
- Sponsor
- Strathmore University
Graft-versus-host-disease (GVHD), Gastrointestinal
Vitamin C With Steroids for Gastrointestinal GVHD
After a transplant from another donor, one risk is graft versus host disease (GVHD) that happens because of differences between the donated cells (graft) and the patient's body cells (host).
- Trial name
- NCT07197749
- Testing
- Vitamin C (Ascorbic Acid)
- Volunteers
- 35 people
- Sponsor
- Baylor College of Medicine
Severe Aplastic Anemia
Avatrombopag Combined With IST as First-line Treatment for SAA
This single-center study aims to evaluate the early efficacy and safety of avatrombopag combined with immunosuppressive therapy (IST) in the first-line treatment of severe aplastic anemia (SAA).
- Trial name
- NCT05720234
- Testing
- avatrombopag
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Diffuse Diabetic Macular Edema
Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema
Diffuse Macular Edema is the main cause of visual disorders in diabetic patients. Diclofenac is a cheap drug available in most of treatment centers.in animal studies the safe dosage is identified that can be used in diffuse…
- Trial name
- NCT00999791
- Testing
- Bevacizumab, Diclofenac
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Acute Graft-versus-host Disease
Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease
This study aims to evaluate the efficacy and safety of low-dose corticosteroids combined with ruxolitinib in the treatment of grade II acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell…
- Trial name
- NCT07576010
- Testing
- RUX+Steroids
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Daihong Liu
Breast Cancer
Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer
This is a prospective, single arm phase II study to evaluate the efficacy and safety of fulvestrant as a maintenance hormone therapy after first-line chemotherapy for postmenopausal HR positive advanced breast cancer.
- Trial name
- FANCY (NCT02000193)
- Testing
- fulvestrant
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-sen University
Neurogenic Bladder
Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder
The purpose of this study is to investigate the use of Botulinum Toxin A as primary therapy for children with neurogenic bladder due to spina bifida and compare results with standard oral oxybutynin therapy.
- Trial name
- NCT01716624
- Testing
- Oxybutynin, Botulinum Toxin A injection
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Chronic Myelogenous Leukemia
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Our goal is to demonstrate that 50mg of dasatinib is as effective as the full dose to induce molecular response as first line therapy in CML.
- Trial name
- NCT03216070
- Testing
- Dasatinib 50 MG
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Malaria
In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso
Resistance to antimalarial drugs represents a major obstacle for controlling malaria in endemic countries, so that most sub-Saharan countries have changed their antimalarial drug policy to the new Artemisinin Containing…
- Trial name
- NCT00808951
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- Burkina Faso
- Volunteers
- 440 people
- Sponsor
- Centre Muraz
NSCLC, Brain Metastasases
A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)
A multicenter, single-arm, open-label study evaluating the safety and efficacy of AK112 combined with chemotherapy as first-line treatment for non-squamous NSCLC patients with BRAIN metastases and negative driver genes
- Trial name
- NCT06684873
- Testing
- AK112 Injection
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University